These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 24416386)

  • 41. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
    Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW
    Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poly-l-Lysine inhibits VEGF and c-Myc mediated tumor-angiogenesis and induces apoptosis in 2D and 3D tumor microenvironment of both MDA-MB-231 and B16F10 induced mice model.
    Debnath S; Mukherjee A; Saha D; Dash J; Chatterjee TK
    Int J Biol Macromol; 2021 Jul; 183():528-548. PubMed ID: 33892042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.
    Biroccio A; Candiloro A; Mottolese M; Sapora O; Albini A; Zupi G; Del Bufalo D
    FASEB J; 2000 Apr; 14(5):652-60. PubMed ID: 10744622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
    Chernoguz A; Crawford K; Donovan E; Vandersall A; Berglund C; Cripe TP; Frischer JS
    J Surg Res; 2012 Mar; 173(1):1-9. PubMed ID: 21658718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
    J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
    Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.
    Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE
    PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro.
    García-Quiroz J; Cárdenas-Ochoa N; García-Becerra R; Morales-Guadarrama G; Méndez-Pérez EA; Santos-Cuevas C; Ramírez-Nava GJ; Segovia-Mendoza M; Prado-García H; Avila E; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2021 Nov; 214():105979. PubMed ID: 34438041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging.
    Stephen RM; Pagel MD; Brown K; Baker AF; Meuillet EJ; Gillies RJ
    Exp Biol Med (Maywood); 2012 Nov; 237(11):1273-80. PubMed ID: 23239438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Muscone derivative ZM-32 inhibits breast tumor angiogenesis by suppressing HuR-mediated VEGF and MMP9 expression.
    Yang LQ; Yu SP; Yang YT; Zhao YS; Wang FY; Chen Y; Li QH; Tian P; Zhu YY; Zhang JG; Lin GQ
    Biomed Pharmacother; 2021 Apr; 136():111265. PubMed ID: 33450490
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
    Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
    Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.
    Xiao YF; Liu SX; Wu DD; Chen X; Ren LF
    World J Gastroenterol; 2006 Sep; 12(36):5780-6. PubMed ID: 17007042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
    Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
    Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoalbaconol inhibits angiogenesis and tumor growth by suppressing EGFR-mediated VEGF production.
    Yu X; Li W; Deng Q; You S; Liu H; Peng S; Liu X; Lu J; Luo X; Yang L; Tang M; Weng X; Yi W; Liu W; Wu S; Ding Z; Feng T; Zhou J; Fan J; Bode AM; Dong Z; Liu J; Cao Y
    Mol Carcinog; 2017 May; 56(5):1414-1426. PubMed ID: 27996164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
    Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
    BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
    Krishnan B; Torti FM; Gallagher PE; Tallant EA
    Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.